Principal Investigators: Drs. David Wood and John Webb
Page template : single-portfolio.php Search terms : Sort : Page : 0
When a patient’s aortic valve becomes narrowed, the heart’s ability to pump blood to reach the rest of the body becomes compromised. Patients develop chest pain and shortness of breath and often die within one to three years. The team at the Centre for Heart Valve Innovation at St. Paul’s Hospital have developed a new approach (the 3M Clinical Pathway), whereby carefully selected patients are awake when they undergo transcatheter aortic valve replacement (TAVR), typically walk 4 hours later, and are safely discharged the following day. The Vancouver 3M Clinical Pathway is an alternative to the more conventional, invasive open-heart surgery.
This is a prospective, multicentre, case-series study. Patients will be selected to undergo TAVR using either the Vancouver 3M Clinical Pathway (400 patients who meet all inclusion and exclusion criteria), or standard care.
The 3M TAVR Multicentre Study is currently documenting the efficacy, feasibility, and safety of next-day discharge of 400 high-risk patients undergoing transfemoral TAVR for severe aortic stenosis using the Vancouver 3M Clinical Pathway. This study will have critical implications for improving outcomes in patients with severe symptomatic aortic stenosis, as well as for the deployment and optimal utilization of health care resources across North America.